S&P 500   3,276.24 (+1.01%)
DOW   28,722.85 (+0.66%)
QQQ   221.45 (+1.54%)
AAPL   317.69 (+2.83%)
FB   217.79 (+1.36%)
MSFT   163.74 (+0.90%)
AMZN   1,853.25 (+1.36%)
BABA   210.90 (+2.64%)
MU   55.41 (+0.00%)
GE   11.75 (+2.62%)
AMD   50.53 (+2.58%)
T   38.58 (+0.86%)
F   8.97 (+0.90%)
NFLX   348.52 (+1.64%)
BAC   33.24 (+1.19%)
DIS   138.34 (+1.80%)
GILD   64.36 (+0.83%)
S&P 500   3,276.24 (+1.01%)
DOW   28,722.85 (+0.66%)
QQQ   221.45 (+1.54%)
AAPL   317.69 (+2.83%)
FB   217.79 (+1.36%)
MSFT   163.74 (+0.90%)
AMZN   1,853.25 (+1.36%)
BABA   210.90 (+2.64%)
MU   55.41 (+0.00%)
GE   11.75 (+2.62%)
AMD   50.53 (+2.58%)
T   38.58 (+0.86%)
F   8.97 (+0.90%)
NFLX   348.52 (+1.64%)
BAC   33.24 (+1.19%)
DIS   138.34 (+1.80%)
GILD   64.36 (+0.83%)
S&P 500   3,276.24 (+1.01%)
DOW   28,722.85 (+0.66%)
QQQ   221.45 (+1.54%)
AAPL   317.69 (+2.83%)
FB   217.79 (+1.36%)
MSFT   163.74 (+0.90%)
AMZN   1,853.25 (+1.36%)
BABA   210.90 (+2.64%)
MU   55.41 (+0.00%)
GE   11.75 (+2.62%)
AMD   50.53 (+2.58%)
T   38.58 (+0.86%)
F   8.97 (+0.90%)
NFLX   348.52 (+1.64%)
BAC   33.24 (+1.19%)
DIS   138.34 (+1.80%)
GILD   64.36 (+0.83%)
S&P 500   3,276.24 (+1.01%)
DOW   28,722.85 (+0.66%)
QQQ   221.45 (+1.54%)
AAPL   317.69 (+2.83%)
FB   217.79 (+1.36%)
MSFT   163.74 (+0.90%)
AMZN   1,853.25 (+1.36%)
BABA   210.90 (+2.64%)
MU   55.41 (+0.00%)
GE   11.75 (+2.62%)
AMD   50.53 (+2.58%)
T   38.58 (+0.86%)
F   8.97 (+0.90%)
NFLX   348.52 (+1.64%)
BAC   33.24 (+1.19%)
DIS   138.34 (+1.80%)
GILD   64.36 (+0.83%)
Log in

NASDAQ:MRTX - Mirati Therapeutics Stock Price, Forecast & News

$90.35
+0.49 (+0.55 %)
(As of 01/28/2020 04:00 PM ET)
Today's Range
$88.07
Now: $90.35
$92.54
50-Day Range
$89.33
MA: $108.98
$128.97
52-Week Range
$55.11
Now: $90.35
$132.59
Volume28,323 shs
Average Volume789,097 shs
Market Capitalization$3.56 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.17
Mirati Therapeutics, Inc, a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company is involved in developing sitravatinib, a spectrum-selective kinase inhibitor, which is in Phase II clinical for the treatment of non-small cell lung cancer (NCSLC); and in Phase Ib clinical trial to treat NCSLC patients with Casitas B-lineage Lymphoma genetic alterations, as well as KRAS G12C inhibitor program for NSCLC adenocarcinoma patients, colorectal cancer patients, and other cancers. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:MRTX
CUSIPN/A
Phone858-332-3410

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$12.93 million
Book Value$5.86 per share

Profitability

Net Income$-98,420,000.00
Net Margins-2,698.66%

Miscellaneous

Employees63
Market Cap$3.56 billion
Next Earnings Date2/27/2020 (Estimated)
OptionableOptionable

Receive MRTX News and Ratings via Email

Sign-up to receive the latest news and ratings for MRTX and its competitors with MarketBeat's FREE daily newsletter.


Mirati Therapeutics (NASDAQ:MRTX) Frequently Asked Questions

What is Mirati Therapeutics' stock symbol?

Mirati Therapeutics trades on the NASDAQ under the ticker symbol "MRTX."

How were Mirati Therapeutics' earnings last quarter?

Mirati Therapeutics Inc (NASDAQ:MRTX) posted its quarterly earnings data on Monday, November, 4th. The biotechnology company reported ($1.38) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.25) by $0.13. The biotechnology company had revenue of $0.99 million for the quarter, compared to analysts' expectations of $0.50 million. Mirati Therapeutics had a negative return on equity of 48.60% and a negative net margin of 2,698.66%. View Mirati Therapeutics' Earnings History.

When is Mirati Therapeutics' next earnings date?

Mirati Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, February 27th 2020. View Earnings Estimates for Mirati Therapeutics.

What price target have analysts set for MRTX?

17 brokers have issued 1-year price targets for Mirati Therapeutics' shares. Their forecasts range from $81.00 to $134.00. On average, they anticipate Mirati Therapeutics' share price to reach $107.93 in the next twelve months. This suggests a possible upside of 19.5% from the stock's current price. View Analyst Price Targets for Mirati Therapeutics.

What is the consensus analysts' recommendation for Mirati Therapeutics?

17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Mirati Therapeutics in the last year. There are currently 1 sell rating, 4 hold ratings and 12 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Mirati Therapeutics.

Has Mirati Therapeutics been receiving favorable news coverage?

Press coverage about MRTX stock has been trending somewhat positive this week, according to InfoTrie. The research firm scores the sentiment of press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Mirati Therapeutics earned a news sentiment score of 0.8 on InfoTrie's scale. They also gave headlines about the biotechnology company a news buzz of 3.0 out of 10, indicating that recent press coverage is unlikely to have an effect on the company's share price in the near future. View News Stories for Mirati Therapeutics.

Who are some of Mirati Therapeutics' key competitors?

What other stocks do shareholders of Mirati Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Mirati Therapeutics investors own include AbbVie (ABBV), Arrowhead Pharmaceuticals (ARWR), Micron Technology (MU), Netflix (NFLX), NVIDIA (NVDA), Viking Therapeutics (VKTX), Bausch Health Companies (BHC), Advanced Micro Devices (AMD), Amarin (AMRN) and Exelixis (EXEL).

Who are Mirati Therapeutics' key executives?

Mirati Therapeutics' management team includes the folowing people:
  • Dr. Charles M. Baum, Pres, CEO & Director (Age 61)
  • Dr. James Christensen, Chief Scientific Officer & Exec. VP (Age 51)
  • Dr. Isan Chen, Exec. VP and Chief Medical & Devel. Officer (Age 57)
  • Mr. Jamie A. Donadio, Sr. VP & CFO (Age 44)
  • Temre Johnson, Director of Investor Relations & Corp. Communications

Who are Mirati Therapeutics' major shareholders?

Mirati Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional investors include Rhenman & Partners Asset Management AB (0.32%), California Public Employees Retirement System (0.16%), Columbus Circle Investors (0.14%), Strs Ohio (0.01%), JGP Global Gestao de Recursos Ltda. (0.01%) and Tocqueville Asset Management L.P. (0.01%). Company insiders that own Mirati Therapeutics stock include Aaron I Davis, Avoro Capital Advisors Llc, Boxer Capital, Llc, Bruce L A Carter, Charles M Baum, Christopher C Lemasters, Craig A Johnson, Jamie A Donadio, Jamie Christensen, Michael G Grey and Venbio Select Advisor Llc. View Institutional Ownership Trends for Mirati Therapeutics.

Which major investors are selling Mirati Therapeutics stock?

MRTX stock was sold by a variety of institutional investors in the last quarter, including California Public Employees Retirement System and Columbus Circle Investors. Company insiders that have sold Mirati Therapeutics company stock in the last year include Avoro Capital Advisors Llc, Boxer Capital, Llc, Bruce L A Carter, Charles M Baum, Christopher C Lemasters, Craig A Johnson, Jamie A Donadio, Michael G Grey and Venbio Select Advisor Llc. View Insider Buying and Selling for Mirati Therapeutics.

Which major investors are buying Mirati Therapeutics stock?

MRTX stock was acquired by a variety of institutional investors in the last quarter, including Rhenman & Partners Asset Management AB, JGP Global Gestao de Recursos Ltda., Tocqueville Asset Management L.P., Strs Ohio, Zurcher Kantonalbank Zurich Cantonalbank and Nisa Investment Advisors LLC. Company insiders that have bought Mirati Therapeutics stock in the last two years include Boxer Capital, Llc and Venbio Select Advisor Llc. View Insider Buying and Selling for Mirati Therapeutics.

How do I buy shares of Mirati Therapeutics?

Shares of MRTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Mirati Therapeutics' stock price today?

One share of MRTX stock can currently be purchased for approximately $90.35.

How big of a company is Mirati Therapeutics?

Mirati Therapeutics has a market capitalization of $3.56 billion and generates $12.93 million in revenue each year. The biotechnology company earns $-98,420,000.00 in net income (profit) each year or ($3.19) on an earnings per share basis. Mirati Therapeutics employs 63 workers across the globe.View Additional Information About Mirati Therapeutics.

What is Mirati Therapeutics' official website?

The official website for Mirati Therapeutics is http://www.mirati.com/.

How can I contact Mirati Therapeutics?

Mirati Therapeutics' mailing address is 9393 TOWNE CENTRE DRIVE SUITE 200, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 858-332-3410 or via email at [email protected]


MarketBeat Community Rating for Mirati Therapeutics (NASDAQ MRTX)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  376 (Vote Outperform)
Underperform Votes:  278 (Vote Underperform)
Total Votes:  654
MarketBeat's community ratings are surveys of what our community members think about Mirati Therapeutics and other stocks. Vote "Outperform" if you believe MRTX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MRTX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/28/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel